Amarin Corporation Plc (AMRN)
| Market Cap | 1.72B |
| Revenue (ttm) | 601.24M |
| Net Income (ttm) | 927,000 |
| Shares Out | 394.77M |
| EPS (ttm) | 0.00 |
| PE Ratio | 2,130.00 |
| Forward PE | 500.00 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $4.26 |
| Previous Close | $4.35 |
| Change ($) | -0.09 |
| Change (%) | -2.07% |
| Day's Open | 4.36 |
| Day's Range | 4.16 - 4.48 |
| Day's Volume | 4,580,487 |
| 52-Week Range | 3.36 - 9.25 |
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Seven Presentations, Including REDUCE-IT® Heart Failure and Additional Analyses from EVAPORATE Amarin-Supported Resea...
Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line.
Shares of Amarin Corp (NASDAQ:AMRN) rose 2.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 100.00% over the past year to ($0.00), which beat the...
Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19 Re...
DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that Joseph T. Kennedy has informed the board of directors of his decision...
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication 1,2, 3
DUBLIN, Ireland and BRIDGEWATER, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior managemen...
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy
The company's CEO announced his retirement.
John Thero to Retire as President and CEO on August 1, 2021
All three companies have enjoyed major growth catalysts since the start of 2021.
This biotech's heart medication could be wildly lucrative.
Reimbursement dossiers for first 10 countries to be filed in coming months
Amarin and Accelerate Diagnostics are healthcare companies with significant upside.
The company won crucial regulatory approval in a massive new market.
The European Commission (EC) has approved the marketing authorization application for Amarin Corporation Plc's (NASDAQ: AMRN) Vazkepa (icosapent ethyl) for cardiovascular risk reduction. The approval co...
Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and other risk characteristics as studie...
HLS Therapeutics Inc announced the Canadian Cardiovascular Society had included icosapent ethyl (Vascepa) in 2021 Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disea...
There are plenty of cheap stocks out there, but don't confuse inexpensive for undervalued; these 10 stocks under $10 should be avoided. The post 10 Cheap Stocks Under $10 That Don't Deserve Your Time or...
Amarin Corporation plc (NASDAQ: AMRN) has announced new prespecified and post hoc analyses from the REDUCE-IT study, evaluating Vascepa (icosapent ethyl). Data were presented at International Stroke Con...
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without...
Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
The drugmaker topped analysts' top- and bottom-line expectations despite challenges from a generic rival and the pandemic.
Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is sched...
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management...
The approval process for its top drug is starting in two major Asian markets.
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that its corporate partner in China, Edding, has progressed VASCEPA® (icosap...
It's been a long and painful path to market success for Amarin. Legal roadblocks devastated the share price and brought generics to market much sooner than expected.
It's all about the incentives.
Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT® cardiovascular outcomes study
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today an expansion of the scope of its VASCEPA® (icosapent ethyl) cardiovascular ...
These stocks have one obvious thing in common.
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ethyl in...
Investors holding shares in these two companies need to practice patience.
Amarin Corporation PLC (AMRN) CEO John Thero Presents at the 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019
Down 77% in 2020, Amarin's stock should zoom higher once Vascepa obtains European approval.
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is sched...
Amarin (AMRN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZeneca's (AZN) nearly $40 billion purchase of Alexion Pharmaceuticals (ALXN), which was annou...
REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reac...
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Two Late Breaker and Six e-Poster Presentations, Including Encore of REDUCE-IT® EPA, Primary Results of the VASCEPA C...
These are the stocks seeing the most insider buying this week
Brian Sullivan on the top companies this week whose executives are purchasing their own stock, on Worldwide Exchange.
Amarin Corporation plc (AMRN) CEO John Thero Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference Call - (Transcript)
About AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commerciali... [Read more...]
| Industry Biotechnology | IPO Date Apr 1, 1993 |
| CEO John Thero | Employees 1,000 |
| Stock Exchange NASDAQ | Ticker Symbol AMRN |
Financial Performance
In 2020, Amarin's revenue was $614.06 million, an increase of 42.89% compared to the previous year's $429.76 million. Losses were -$18.00 million, -20.51% less than in 2019.
Analyst Forecasts
According to 12 analysts, the average rating for Amarin stock is "Buy." The 12-month stock price forecast is 10.25, which is an increase of 140.61% from the latest price.